Myovant Sciences Ltd. Common Shares (MYOV): Price and Financial Metrics
MYOV Price/Volume Stats
| Current price | $26.98 | 52-week high | $27.06 |
| Prev. close | $26.99 | 52-week low | $7.67 |
| Day low | $26.98 | Volume | 2,256,000 |
| Day high | $27.00 | Avg. volume | 1,169,678 |
| 50-day MA | $26.92 | Dividend yield | N/A |
| 200-day MA | $21.14 | Market Cap | 2.62B |
MYOV Stock Price Chart Interactive Chart >
Myovant Sciences Ltd. Common Shares (MYOV) Company Bio
Myovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for women’s health diseases and other endocrine-related disorders. The company was founded in 2016 and is based in Hamilton, Bermuda.
Latest MYOV News From Around the Web
Below are the latest news stories about MYOVANT SCIENCES LTD that investors may wish to consider to help them evaluate MYOV as an investment opportunity.
Myovant Sciences (MYOV) Reports Q3 Loss, Lags Revenue EstimatesMyovant Sciences (MYOV) delivered earnings and revenue surprises of -5.36% and 3.44%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock? |
Myovant Sciences Announces Corporate Updates and Financial Results for Third Fiscal Quarter 2022Third fiscal quarter 2022 total revenue of $100.2 million; including net product revenue of $61.4 millionNet product revenue from U.S. sales of ORGOVYX® of $48.7 million in third fiscal quarter 2022, with sequential quarterly demand volume growth of 13% and cumulative patients estimated at 26,000 through December 2022Net product revenue from U.S. sales of MYFEMBREE® of $10.5 million in third fiscal quarter 2022, with sequential quarterly demand volume growth of 49% and cumulative patients estima |
Lynn Seely steps into top role at cancer-fighting company Lyell ImmunopharmaSeely steps into the top operational roles at a company where outgoing president and CEO Liz Homans guided two cancer cell therapies into the clinic. |
Myovant Sciences Announces New Employment Inducement Grants Under NYSE Rule 303A.08BASEL, Switzerland, Nov. 16, 2022 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a biopharmaceutical company that aspires to redefine care for women and for men through purpose-driven science, empowering medicines, and transformative advocacy, today announced that it approved equity awards for 18 new employees with a grant date of November 15, 2022 pursuant to Myovant’s 2020 Inducement Plan. The equity awards were granted to the employees joining Myovant in accordance with NYSE’s Listed Comp |
Myovant Sciences Appoints Ann Tomlin as Senior Vice President of Human ResourcesBASEL, Switzerland, Nov. 16, 2022 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV) today announced the appointment of Ann Tomlin as Senior Vice President of Human Resources. Beginning November 28, Ms. Tomlin will be responsible for developing talent solutions and human resources strategies across Myovant’s global functions. She will serve as a member of the Executive Committee and will report to David Marek, Myovant’s Chief Executive Officer. Ms. Tomlin has over 25 years of human resources expe |
MYOV Price Returns
| 1-mo | N/A |
| 3-mo | N/A |
| 6-mo | N/A |
| 1-year | 56.41% |
| 3-year | 30.21% |
| 5-year | 1.62% |
| YTD | 0.07% |
| 2022 | 73.15% |
| 2021 | -43.63% |
| 2020 | 77.96% |
| 2019 | -5.42% |
| 2018 | 29.83% |
Loading social stream, please wait...